Your browser doesn't support javascript.
loading
[Should patients with ANCA-associated vasculitis undergoing maintenance therapy with rituximab receive cotrimoxazole prophylaxis?] / Sollten Patienten mit ANCA-assoziierten Vaskulitiden (AAV), die eine Erhaltungstherapie mit Rituximab erhalten, eine Cotrimprophylaxe bekommen?
Mahrhofer, Hartmut.
Affiliation
  • Mahrhofer H; Klinik für Innere Medizin, Rheumatologie, Pneumologie Nephrologie und Diabetologie. Rheumazentrum (GBA) des Landes Baden-Württemberg Europäisches Vaskulitis-Referenzzentrum (ERN-RITA), medius Klinik Kirchheim, Eugenstr. 3, 73230, Kirchheim-Teck, Deutschland. h.mahrhofer@medius-kliniken.de.
Z Rheumatol ; 83(2): 122-124, 2024 Mar.
Article in De | MEDLINE | ID: mdl-38272971
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Trimethoprim, Sulfamethoxazole Drug Combination / Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Type of study: Risk_factors_studies Limits: Humans Language: De Journal: Z Rheumatol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Trimethoprim, Sulfamethoxazole Drug Combination / Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Type of study: Risk_factors_studies Limits: Humans Language: De Journal: Z Rheumatol Year: 2024 Document type: Article Country of publication: